Skip to main content
Evidence Snapshot

DLD-1

CHEMBL614285 CELL-LINE Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T14:38:34Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL614285
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats DLD-1 as ChEMBL target CHEMBL614285. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
DLD-1
CELL-LINE · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL614285
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why DLD-1 matters

As of 2026-09-13

DLD-1 is reviewed as DLD-1; the current evidence base includes 28 approved drugs, 15630 compounds, and 659 assays, with lead potency reaching pChEMBL 10.5.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 28 approved drugs, 15630 compounds, and 659 assays for this target. The dominant activity type is IC50. CHEMBL4544901 is the current potency anchor at pChEMBL 10.5.

Use CHEMBL4544901 as the tractability anchor when discussing potency (pChEMBL 10.5).

Activity source · ChEMBL 36 via Core Engine
28 approved pChEMBL 10.5
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why DLD-1 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

15630
Total Compounds
659
Total Assays
28
Approved Drugs
IC50: 1794.0, EC50: 243.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4544901
 10.5 IC50 —
No preferred name
CHEMBL4593271
 10.0 IC50 —
No preferred name
CHEMBL1683602
 9.8 IC50 —
No preferred name
CHEMBL4448361
 9.7 IC50 —
No preferred name
CHEMBL1683528
 9.7 IC50 —

Approved Drugs

Structure Compound First Approval
TALAZOPARIB
CHEMBL3137320
 2018
NIRAPARIB
CHEMBL1094636
 2017
RUCAPARIB
CHEMBL1173055
 2016
OLAPARIB
CHEMBL521686
 2014
ERIBULIN
CHEMBL1683590
 2010
VORINOSTAT
CHEMBL98
 2006
PACLITAXEL
CHEMBL428647
 1992
PODOFILOX
CHEMBL61
 1990
AMSACRINE
CHEMBL43
 1987
ETOPOSIDE
CHEMBL44657
 1983
DOXORUBICIN
CHEMBL53463
 1974
FLOXURIDINE
CHEMBL917
 1970
VINBLASTINE
CHEMBL159
 1965
COLCHICINE
CHEMBL107
 1961
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T14:38:34Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL614285